1 Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on

2

disease modifying therapies

3	Maria Pia Sormani ^{1,2} , Irene Schiavetti ¹ , Matilde Inglese ^{2,3} , Luca Carmisciano ¹ , Alice Laroni ^{2,3} , Caterina
4	Lapucci ^{2,3} , Valeria Visconti ⁴ , Carlo Serrati ⁵ , Ilaria Gandoglia ⁶ , Tiziana Tassinari ⁷ , Germana Perego ⁸ ,
5	Giampaolo Brichetto ⁹ , Paola Gazzola ¹⁰ , Antonio Mannironi ¹¹ , Maria Laura Stromillo ¹² , Cinzia Cordioli ¹³ ,
6	Doriana Landi ¹⁴ , Marinella Clerico ¹⁵ , Elisabetta Signoriello ¹⁶ , Jessica Frau ¹⁷ , Maria Teresa Ferro ¹⁸ , Alessia
7	Di Sapio ¹⁹ , Livia Pasquali ²⁰ , Monica Ulivelli ²¹ , Fabiana Marinelli ²² , Marcello Manzino ²³ , Graziella Callari ²⁴ ,
8	Rosa Iodice ²⁵ , Giuseppe Liberatore ²⁶ , Francesca Caleri ²⁷ , Anna Maria Repice ²⁸ , Susanna Cordera ²⁹ , Mario
9	Alberto Battaglia ^{30,31} , Marco Salvetti ^{32,33} , Diego Franciotta ^{34*} , Antonio Uccelli ^{2,3*} and the CovaXiMS study
10	group.
11	*These authors have contributed equally to the manuscript.
10	
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	 Department of Health Sciences, Section of Biostatistics, University of Genova, Italy IRCCS Ospedale Policlinico San Martino, Genova, Italy Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy Laboratory Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy Department of Neurology, Imperia Hospital, Imperia, Italy Neurology Unit, Galliera Hospital S.C. Neurologia - Ospedale Santa Corona Pietra Ligure (Sv) SC Neurologia ASL 4 Chiavarese AISM Rehabilitation Center, Genoa, Italy Centro Sclerosi Multipla S.C. Neurologia Asl 3 Genovese Department of Neurology, Sant'Andrea Hospital, La Spezia, Italy Clinica Neurologica e Malattie Neurometaboliche, Università degli Studi di Siena Centro Sclerosi Multipla ASST Spedali Civili di Brescia
27 28 29	 Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University and Hospital, Rome, Italy Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Università di Torino,
30	16. Centro Sclerosi Multipla, II Clinica Neurologica, Università della Campania Luigi Vanvitelli
31	17. Centro Sclerosi Multipla Ospedale Binaghi Cagliari - ATS Sardegna, Università di Cagliari
32	18. Neuroimmunology, Center for Multiple Sclerosis, Cerobrovascular Department, Neurological Unit, ASST
33	Crema
34 25	19. Department of Neurology, Regina Montis Regalis Hospital, Mondovi, Italy 20. Department of Clinical and Experimental Medicine, Neurology, Unit, University of Disc. Italy
36	20. Department of Chinical and Experimental Medicine, Neurology Unit, University of Pisa, Italy 21. Department of Medicine, Surgery and Neuroscience, University of Siena
37	22. Multiple Sclerosis Center, Fabrizio Spaziani Hospital, via Armando Fabi, Frosinone – Italy
38	23. Neurologia, Ospedale San Paolo, Savona, Italy
39	24. UOC Neurologia e Centro SM Fondazione Istituto G. Giglio, Cefalù
4.0	

40 25. Clinica Neurologica, DSNRO Università Federico II di Napoli

41 42 43 44 45 46 47 48 49 50	 Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Research Hospital, Rozzano, Italy MS Center, Department of Neurology, F. Tappeiner Hospital Meran (BZ), Italy Department of Neurology 2, Careggi University Hospital, Florence, Italy Department of Neurology, Ospedale Regionale, Aosta, Italy Research Department, Italian Multiple Sclerosis Foundation, Genoa, Italy Department of Life Sciences, University of Siena, Italy Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Italy IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli, Italy Autoimmunology Laboratory, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
51	
52	Corresponding author: Maria Pia Sormani, Department of Health Sciences, Via Pastore 1, 16132,
53	University of Genova, Italy
54	Email: mariapia.sormani@unige.it
55	Tel: +39-3669937472
56	
57	Keywords: Multiple Sclerosis, Covid-19 vaccination, Breakthrough infections
58	Number of characters in the title: 99
59	Number of words: 2611
60	Number of figures: 2
61	Number of Tables: 3
62	Number of references: 17
63	

64 Abstract

65 Background. Patients with Multiple Sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a 66 reduced humoral response to mRNA-based SARS-CoV-2 vaccines, while the degree of such responses is 67 unimpaired and similar in pwMS treated with other disease modifying therapies (DMTs), or untreated. However, the nature of the SARS-CoV-2 vaccine-induced immune response is based also on cellular 68 69 immunity and there is emerging evidence that anti-SARS-CoV-2 specific CD4 and CD8 T cell responses can 70 be detected after vaccination also in patients with low antibody levels. In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection and to identify correlates of reduced protection in frail 71 72 vaccinated pwMS on different DMTs.

Methods. We designed a long term clinical follow-up of the CovaXiMS (Covid-19 vaccine in Multiple Sclerosis), a prospective multicenter cohort study enrolling pwMS scheduled for SARS-CoV-2 vaccination with mRNA vaccines and tested for SARS-CoV-2 antibodies before and after the second vaccine dose. These patients were followed with periodic phone calls up to a mean time of 6 months, and all the SARS-CoV-2 breakthrough infections were registered. The impact of DMTs on cumulative incidence of breakthrough Covid-19 cases was presented by Kaplan-Meier curves. A multivariable logistic model was run to assess factors associated to a higher risk of breakthrough infections.

80 Findings. 1705 pwMS (81.6% BNT162b2 and 18.4% mRNA-1273) had a full vaccination cycle (2 vaccine 81 doses, 21/28 days apart). Of them, 1509 (88.5%) had blood assessment 4 weeks after the second vaccine 82 dose. During follow-up, 23 breakthrough Covid-19 infections (cumulative incidence: 1.5%, SE=0.3%) were 83 detected after a mean of 108 days after the second dose (range, 18-230). Of them, 9 were on ocrelizumab, 84 one on rituximab, 4 on fingolimod, 6 on dimethyl-fumarate, one on teriflunomide, and 2 were untreated. Just 85 two cases (a woman on ocrelizumab and a man on teriflunomide) required hospitalization. The probability to 86 be infected was associated only with SARS-CoV-2 antibody levels measured after 4 weeks from the second 87 vaccine dose (HR=0.63, p=0.007); an antibody level of 660 U/mL was calculated as the cutoff for higher risk 88 of infection.

- 89 Interpretation. Our data show that the risk of breakthrough SARS-CoV-2 infections is mainly associated
- 90 with reduced levels of the virus-specific humoral immune response.
- 91 Funding. FISM [2021/Special-Multi/001]; the Italian Ministry of Health grant 'Progetto Z844A 5x1000'.
- 92 Italian Ministry of Health: Ricerca Corrente to IRCCS Ospedale Policlinico San Martino.

94 Introduction

Evidence of the effect of vaccination against SARS-CoV-2, mainly on virus-specific serological responses¹⁻³ 95 and, to a minor extent, on antigen-specific T cell response^{4,5} in patients with MS (pwMS) treated with 96 97 disease-modifying therapies (DMTs) is rapidly accumulating. There is wide consensus that the use of anti-98 CD20 monoclonal antibodies and fingolimod are associated with the lowest serum SARS-CoV-2 antibody 99 concentrations, following the SARS-CoV-2 vaccines, whereas virus-specific humoral immune responses in 100 pwMS on all the other DMTs, or untreated, were high and did not differ significantly from healthy controls ¹⁻ 101 ⁴. On the other hand, there is also growing evidence that vaccinated pwMS treated with anti-CD20 generated robust virus specific CD4 and CD8 T cell responses⁴⁻⁵, while these are slightly reduced in fingolimod treated 102 patients⁵. Indeed, Covid-19 vaccination is less immunogenic in immunocompromising conditions⁶ and there 103 104 is evidence that both serum SARS-CoV-2 antibody levels and the degree of vaccine-induced protection from Covid-19 decline with time since vaccination^{7,8}. Thus, it is mandatory to monitor the incidence of 105 106 breakthrough infections in pwMS, to better understand the role of humoral and cellular response to SARS-107 CoV-2 vaccination in preventing Covid-19 and its consequences. A preliminary follow-up study of 344 fully 108 vaccinated people with multiple sclerosis on disease modifying therapy reported 13 breakthrough infections, 109 10 of which were in patients under anti-CD20 therapy and the remaining 3 on fingolimod⁹.

We planned a clinical follow-up of the pwMS enrolled in the CovaXiMS (Covid-19 vaccine in Multiple Sclerosis)¹, a prospective multicenter cohort study enrolling Covid-19 vaccinated pwMS, in whom SARS-CoV-2 antibodies were measured before the first and 4 weeks after the second vaccine dose. Aim of the study was to evaluate the incidence of breakthrough infections in relation to baseline characteristics and vaccination-elicited antibody levels, and to identify possible correlates of a reduced protection against the disease and its severe form.

116

117 Patients and Methods

118 Study design and participants

119 This was a clinical follow-up of an observational multicenter prospective study conducted in 35 Italian MS 120 centers on pwMS undergoing the SARS-CoV-2 vaccination. Adult pwMS, with or without a previous 121 SARS-CoV-2 infection, who were scheduled for SARS-CoV-2 vaccination, were included in the study. 122 mRNA vaccines BNT162b2 (Pfizer Inc, and BioNTech), or mRNA-1273 (Moderna Tx, Inc) as per clinical 123 practice and regional indications were allowed. Patients who agreed to provide a first blood test sample just 124 before the vaccination and a second drawing one month after the last dose were enrolled in the study. 125 Patients were then followed up, with monthly phone calls and visits as per clinical practice, and any new 126 SARS-CoV-2 infection, or the occurrence of Covid-19 infection was recorded in a dedicated Case Report 127 Form (CRF).

The study is done in compliance with the principles of the Declaration of Helsinki. The protocol is approved by the regional (CER Liguria: 5/2021 - DB id 11169- 21/01/2021) and the centralized national ethical committee AIFA/Spallanzani (Parere n 351, 2020/21). Written informed consent was obtained from all participants before starting any study procedures.

132

133 *Study procedures*

Eligible subjects were contacted by their neurologist 3 months after the second vaccine dose against Covid-135 19 and then contacted every month. Data of patients who had a PCR-confirmed Covid-19 diagnosis were 136 collected in a dedicated CRF including information on symptoms and severity of the disease.

137

138 Primary Outcome: breakthrough infection

The primary objective of this analysis was to quantify the incidence of breakthrough SARS-CoV-2 infection among the vaccinated pwMS included in the CovaXiMS study. These conditions entail a PCR-confirmed swab, and a time lag of at least 14 days from the second vaccination dose.

142

143 SARS-CoV-2 antibody measurement

High-affinity pan-Ig antibodies to SARS-CoV-2 were measured by a centralized laboratory with a doubleantigen sandwich-based electrochemiluminescence immunoassay (Elecsys®, Roche Diagnostics Ltd,
Switzerland). Receptor-binding domain (RBD) antibodies were quantitatively measured to evaluate the
humoral immune response to the two RBD-coding mRNA vaccines. RBD antibodies have been shown to
positively correlate with SARS-CoV-2 neutralizing antibodies on neutralization assays¹⁰⁻¹¹. Serum samples
were shipped in dried ice by the centers and stored at -20°C until analysis.

150 Statistical analysis

The cumulative incidence of breakthrough infections in the different DMT groups was reported by Kaplan-Meier survival curves. A multivariable Cox model was used to evaluate the impact of DMT class and antibody levels developed 4 weeks after the second vaccination dose on the risk of a breakthrough infection after adjusting for age, sex, BMI, EDSS level, disease duration, presence of comorbidities and vaccine type. The antibody levels were transformed on a Log10 scale, to normalize their distribution and according to previous literature¹. A ROC curve (run on the subgroup of patients with at least 6 months of follow-up) was used to assess the best antibody level cut-off indicating a protective level against breakthrough infections.

158 Results

Data were collected between March 4, 2021 and December 15, 2021. At the time of analysis, we had data on 160 1705 pwMS (81.6% BNT162b2 and 18.4% mRNA-1273) who had a full vaccination cycle (2 vaccine doses, 161 21/28 days apart). Of them, 1509 (88.5%) had blood assessment 4 weeks after the second vaccine dose. The 162 median follow-up after the second vaccine dose was 222 days (range, 44-328). The patients' characteristics 163 and the number of vaccinated patients in each DMT group are reported in Table 1.

164 Overall, we observed 23 Covid-19 cases during follow-up reported after a mean of 105 days after the second

dose (range, 18-232). Nine of them were on ocrelizumab, one on rituximab, 4 on fingolimod, 6 on dimethyl-

- 166 fumarate, one on teriflunomide, and 2 were untreated. The 8-month cumulative incidence of breakthrough
- 167 infection was 1.5% (SE, 0.3%) (Figure 1, panel a). The incidence was higher in pwMS on ocrelizumab
- 168 (4.0%, SE=1.0%), fingolimod (2.3%, SE=1.2%), rituximab (2.1%, SE=2.2%) or dimethyl-fumarate (2.3%,
- 169 SE=0.9%), as compared to teriflunomide (1.0%, SE=1.0%), and untreated patients (0.8%, SE, 0.6%), and it

170 was zero for all the other therapies (figure 1, panel b). The log-rank test for heterogeneity among DMTs was 171 borderline significant (p=0.052). Grouping anti-CD20 (ocrelizumab and rituximab) vs fingolimod vs other 172 drugs (Figure 1, panel c) gave a highly significant heterogeneity p<0.001 (Figure 1, panel b). 173 At multivariable analysis the only significant factor associated to the risk of breakthrough infection was the 174 antibody level after the second dose, with an HR of 0.63 (95%CI=0.45-0.87), p=0.007. This value indicates 175 that the risk of breakthrough infection is reduced by 37% every X10 increase in the antibody level. The ROC 176 curve applied to patients with at least 6 months of follow-up (n=1474, 97.7%) inicated a value of log 177 antibody level of 2.82 (660 U/mL) as the best cutoff discriminating those at a higher risk of infection 178 (AUC=0.71; sensitivity, 88%, specificity, 58%). Figure 2 reports the breakthrough infections in each DMT 179 group and according to antibody levels. Two patients (one in ocrelizumab and one in fingolimod) who had a 180 breakthrough infection, had their blood sample taken after Covid-19. Both patients developed very high 181 antibody levels after Covid-19.

Two patients, a woman on ocrelizumab with a very low antibody titer (5 U/mL) and a man on teriflunomide
with medium antibody titer (610 U/mL), were hospitalized after Covid-19, but recovered without the need
for supplemental oxygen.

185

186 Discussion

187 The risk of both contracting SARS-CoV-2 infection and of not responding to Covid-19 vaccines is higher in 188 pwMS on anti-CD20 monoclonal antibodies or fingolimod. Vaccine-induced protection from the disease is expected to waning with time since vaccination^{7,8} and different levels of immunity impact on susceptibility to 189 190 breakthrough infections. In this study we assessed the incidence of breakthrough infections in a large Italian 191 cohort of patients fully vaccinated with mRNA vaccines. The cumulative incidence of breakthrough 192 infection over a follow-up of 8 months was 1.5%, with some heterogeneities among groups treated with 193 different DMTs. However, since the cases are few, a test for heterogeneity among more than 10 groups 194 taking different DMTs has low statistical power. A Cox model, including the antibody level as a continuous 195 variable and adjusted for the main baseline covariates, revealed that lower SARS-CoV-2 antibody levels as 196 the only relevant risk factor for breakthrough infections. The risk of infection decreases of about 37% for 197 every 10 times-fold increase in the antibody levels. In this study, SARS-CoV-2 antibody level equal to, or 198 lower than 660 U/mL are associated with higher risk of infection in the subsequent 6 months. Post-199 vaccination neutralizing antibody titers predicted the risk of breakthrough infection in health care workers¹² 200 However, no neutralizing or binding antibody threshold titer identified so far can predict the degree of 201 protection, depending on unpredictable titer changes over time and on the strength of immunity at the 202 moment when a subject is exposed. In addition, other SARS-CoV-2 infection risk modifiers, such as each 203 patient's safety precautions and viral load exposure amount, can impact on the risk of Covid-19 204 independently from antibody titers.

On the other hand, the main goal of vaccination is not to prevent infections, but rather to prevent the severe disease. In this respect, we observed just two breakthrough infections that caused Covid-19 requiring hospitalization followed by resolution within one week. The prevalence of hospitalization in our Italian Covid-19 cohort of pwMS in the pre-vaccination era was 12.8%¹³ and therefore around 2 cases were expected out of the 22 infected patients. Therefore, these numbers are too low to draw conclusions from this observation.

Analogously to the other study on anti-CD20 treated patients following Covid-19 vaccination¹⁴, the age factor, which typically associate with lower antibody responses to Covid-19 vaccines¹⁵, did not have an independent role on influencing the risk of breakthrough infections in our pwMS cohort, when we take into account the antibody levels. This phenomenon appears to be evident in the general population too¹⁶.

This study has some limitations. First, incidence data of breakthrough infections in the general population, as well as those of non-breakthrough infections in unvaccinated people, were not available for comparing these rates with those of our pwMS cohort. In solid organ transplant recipients, the diminished antibody responses to SARS-CoV-2 resulted in 41-to-82-fold (depending on the statistical approach) higher risk of breakthrough infection vs general population¹⁷. Second, we have no data on SARS-CoV-2 molecular characterization, as the Delta variant reduces vaccine effectiveness¹⁷, but high enough SARS-CoV-2 antibody titers can protect against infection and severe outcomes¹⁸. 222 In conclusion, the results of this study suggest that the rates of breakthrough infections in pwMS on DMTs at 223 least partially depends on the level of humoral immunity to SARS-CoV-2, which, is reduced in patients 224 under specific DMTs and that declines over time. Larger cohorts are needed to understand the protective role 225 of vaccination for severe Covid-19 in pwMS under different DMTs. It is likely that the protection from 226 Covid-19 might increase after breakthrough infections, or after subsequent vaccine doses. Identifying the 227 frequency, severity, and predisposing factors of breakthrough infections in frail patients may inform how to 228 protect them with anticipates boosting doses of vaccines. The recommended safety precautions, such as 229 masks and distancing, should remain a mainstay to reduce the incidence of SARS-CoV-2 infection.

230 Acknowledgements

Supported by FISM [2021/Special-Multi/001]; the Italian Ministry of Health grant 'Progetto Z844A 5x1000'
to the IRCCS Ospedale Policlinico San Martino (D.F.) and the Italian Ministry of Health: Ricerca Corrente
to IRCCS Ospedale Policlinico San Martino. We thank Barbara Uggeri, Claudio Spallarossa, and Giovanni
Rossi for their excellent laboratory assistance.

References

237	1.	Sormani MP, Inglese M, Schiavetti I et al. Effect of SARS-CoV-2 mRNA vaccination in MS
238		patients treated with disease modifying therapies. EBioMedicine. 2021 Oct;72:103581. doi:
239		10.1016/j.ebiom.2021.103581.
240	2.	Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA
241		vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
242		Ther Adv Neurol Disord. 2021. doi:10.1177/17562864211012835
243	3.	Tallantyre EC, Vickaryous N, Anderson V et al. COVID-19 Vaccine Response in People with
244		Multiple Sclerosis. Ann Neurol 2021; Oct 22. doi: 10.1002/ana.26251. Online ahead of print
245	4.	Tortorella C, Aiello A, Gasperini C et al. Humoral- and T-Cell-Specific Immune Responses to
246		SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying
247		Therapies. Neurology in press
248	5.	Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following
249		SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med.
250		2021 Nov;27(11):1990-2001. doi: 10.1038/s41591-021-01507-2.
251	6.	Kearns, P. et al. Examining the immunological effects of COVID-19 vaccination in patients with
252		conditions potentially leading to diminished immune response capacity - The OCTAVE Trial. SSRN
253		https://doi.org/10.2139/ssrn.3910058 (2021)
254	7.	X. Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl.
255		J. Med. 384, 80–82 (2021).
256	8.	Y. Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a
257		longitudinal prospective study. Lancet Reg. Health Eur. 10, 100208 (2021).
258	9.	Rose DR, Mahadeem AZ, Carlson AK et al. Clinical features and outcomes of COVID-19 despite
259		SARS-CoV-2 vaccination in people with multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Nov
260		26;7(4):20552173211057110. doi: 10.1177/20552173211057110. eCollection 2021 Oct.
261	10.	Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-
262		throughput SARS-CoV-2 IgG antibody assays. J Clin Virol. 2020. doi:10.1016/j.jcv.2020.104480

263	11. Müller L, Ostermann PN, Walker A, et al. Sensitivity of anti-SARS-CoV-2 serological assays in a
264	high-prevalence setting. Eur J Clin Microbiol Infect Dis. 2021. doi:10.1007/s10096-021-04169
265	12. Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J.
266	Med. 385, 1474–1484 (2021).
267	13. Sormani MP, Schiavetti I, Carmisciano L et al. COVID-19 Severity in Multiple Sclerosis: Putting
268	Data Into Context. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1):e1105. doi:
269	10.1212/NXI.00000000001105. Print 2022 Jan.
270	14. Natacha Madelon et al. Robust T cell responses in anti-CD20 treated patients following COVID-19
271	vaccination: a prospective cohort study. Clin Infect Dis. 2021 Nov 17;ciab954. doi:
272	10.1093/cid/ciab954. Online ahead of print
273	15. Lustig, Y. et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and
274	dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet
275	Respir. Med. 9, 999–1009 (2021).
276	16. Scobie, H. M. et al. Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by
277	vaccination status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR 70, 1284-1290 (2021).
278	17. Tang, P. et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta
279	(B.1.617.2) variant in Qatar. Nat. Med. https://doi.org/10.1038/s41591-021-01583-4 (2021).
280	18. Bar-On, Y. M. et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J.
281	Med. 385, 1393–1400 (2021).
282	

283 Figure legends

284	Figure 1: Kaplan Meier survival curves displaying the cumulative probability of a breakthrough
285	infection in the whole cohort (panel a), in each disease modifying therapy group (panel b) and in
286	groups defined by patients treated by anti-CD20 drugs (ocrelizumab or rituximab), by fingolimod
287	and other therapies (panel c).
288	Figure 2: Covid-19 cases (red dots) and severe Covid-19 cases (hospitalized) (red stars) according
289	to disease modifying therapy and antibody level.

291 Table 1: Baseline characteristics of patients with multiple sclerosis who received two vaccine

292

doses

293

294

Characteristics	Overall (N = 1705)
Age, years (mean, SD)	46.1 (12.45)
Females (n, %)	1161 (68.1%)
BMI, kg/m² (mean, SD)	24.1 (3.65)
MS phenotype (n, %)	
Relapsing remitting	1420 (83.3%)
Secondary progressive	158 (9.3%)
Primary progressive	127 (7.4%)
MS disease duration, years (median, IQR)	10.0 [5.0 - 15.6]
EDSS (median, IQR)	2.0 [1.0 - 4.0]
MS treatment (n, %)	
Ocrelizumab	272 (16.0%)
Dimethyl fumarate	267 (15.7%)
Natalizumab	199 (11.7%)
Interferon	192 (11.3%)
Fingolimod	173 (10.1%)
Teriflunomide	102 (6.0%)
Glatiramer acetate	102 (6.0%)
Cladribine	51 (3.0%)
Rituximab	48 (2.8%)
Alemtuzumab	23 (1.3%)
Other	26 (1.5%)
Untreated	250 (14.7%)
Vaccine product (n, %)	
mRNA BNT162b2	1347 (79.0%)
mRNA-273	314 (18.4%)
Not specified	44 (2.6%)

295

296 MS=Multiple Sclerosis, BMI=Body Mass Index, SD=Standard Deviation, IQR=Interquartile Range,

297 EDSS=Expanded Disability Status Scale.

Table 2. Multivariable Cox regression model evaluating risk factors for breakthrough SARS CoV-2 infections.

	Multivariable Analysis*	
	n=1500	
Variable	HR (95% C.I.)	р
Antibody levels (log10)	0.64 (0.46-0.89)	0.009
Age (years)	0.98 (0.94-1.03)	0.44
Sex (Female vs Male)	0□51 (0.20-1.30)	0.16
EDSS	0.96 (0.73-1.26)	0.77
Vaccine (mRNA-1273 vs mRNA BNT162b2)	0.92 (0.31-2.75)	0.88

301 302

HR=Hazard Ratio, C.I.=Confidence Interval, EDSS=Expanded Disability Status Scale

Figure 1: Kaplan Meier survival curves displaying the breakthrough infections cumulative probability overall in the vaccinated cohort (panel a), in
 groups according to disease modifying therapy (panel b) and in groups according to treatment with anti-CD20, fingolimod and other drugs (panel c).





